Last updated on June 2017

Open-Label Multi-Center Two-Part Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Brief description of study

This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg tazemetostat that contains approximately 400 µCi of [14C]-labeled tazemetostat in three subjects with B-cell lymphomas.

Clinical Study Identifier: NCT03010982


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Harry Miao, MD, PhD

The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, United Kingdom
  Connect »

Harry Miao, MD, PhD

Royal Liverpool and Broadgreen University Hospital Trust
Liverpool, United Kingdom
  Connect »